

Table 12

In this guide

[In this guide](#)

1. [Table 3 - Annex A](#)
2. [Table 4 - Annex A](#)
3. [Table 5 - Annex A](#)
4. [Table 6 - Annex A](#)
5. [Table 7 - Annex A](#)
6. [Table 8 - Annex A](#)
7. [Table 9 - Annex A](#)
8. [Table 10 - Annex A](#)
9. [Table 11 - Annex A](#)
10. [Table 12 - Annex A](#)
11. [Table 13 - Annex A](#)
12. [Table 14 - Annex A](#)
13. [Table 15 - Annex A](#)
14. [Table 16 - Annex A](#)
15. [Table 17 - Annex A](#)
16. [Table 18 - Annex A](#)
17. [Table 19 - Annex A](#)
18. [Table 20 - Annex A](#)
19. [Table 21 - Annex A](#)

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

Table 12. Repeated dose toxicity studies for PFCAs - PFUnDA

*Derived by contractor; ** calculated according to EFSA. (2012); NR – not reported; NA – not applicable.

Substance / CAS no. / purity / reference	Strain & / species / sex / no. of animals	Dose (mg/kg bw/day) / vehicle / route of admin / duration / Guideline (GL) study) / Good Laboratory Practice (GLP) status	PFAS concentration (µg/mL / µg/g	Observed effects at LOAEL (controls vs treated groups). Recovery (controls vs treated groups).	Published NOAEL / LOAEL (mg/kg bw/day)	Study author comment

					Males (mean \pm SD):		
					\uparrow relative liver weight (%): 2.88 ± 0.27 vs $3.39 \pm 0.16^{\#}$.		Data suggests the liver is sensitive to this target compound as the liver weight increases in the centrilobular hypertrophy of hepatocytes was seen in both sexes and focal necrosis and/or diffuse vacuolation of hepatocytes was seen at higher doses.
					\downarrow total cholesterol (mg/dL): 56 ± 14 vs $34 \pm 6^{\#}$.		
		0, 0.1, 0.3 or 1.			\uparrow albumin/globulin ratio: 0.80 ± 0.07 vs $0.93 \pm 0.05^{\#}$.	Males:	
PFunDA	Crl:CD (SD) rats.	Gavage, 42 days (males),			\uparrow hepatocyte centrilobular hypertrophy: 0 vs 3 (2 minimal; 1 mild).	0.1 / 0.3.	
CAS No. 2058-94-8	Male and female.	41-46 days (females),	NR		Females:	Females: 0.1 / 0.3.	
98.5%.	12/sex/dose.	OECD 422, GLP not stated.			\downarrow total cholesterol (mg/dL): 60 ± 11 vs $41 \pm 13^{\#}$.		
Takahashi et al. (2014)	Recovery: 5 males and females.	Recovery: 0 or 1, 14 days .			\uparrow hepatocyte centrilobular hypertrophy: 0 vs 1 (1 minimal).		The NOAEL for repeated dose toxicity was 0.1 mg/kg bw/day based on centrilobular hypertrophy of hepatocytes in both sexes at 0.1 mg/kg bw/day
					Recovery:		
					Data not presented as animals only treated with 200 mg/kg bw/day and not 0.3		

